TIRZEPTIDE INJECTION

Tirzepatide is indicated to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

Tirzepatide is also indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. Tirzepatide has demonstrated significant benefits in obese patients with a common type of heart failure, preserved ejection fraction (HFpEF) in a Phase 3 trial. Over two years, tirzepatide reduced the risk of major com

plications, including urgent heart failure visits, hospitalizations, increased diuretic treatment, and cardiovascular-related deaths, by 38% compared to placebo. This makes tirzepatide the second GLP-1 drug to show positive results in this area, following

semaglutide, to date.